12/1
07:03 am
nmra
Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at Royal Bank Of Canada from a "sector perform" rating to an "outperform" rating.
Neutral
Report
Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at Royal Bank Of Canada from a "sector perform" rating to an "outperform" rating.
11/17
09:21 am
nmra
Neumora Therapeutics (NASDAQ:NMRA) had its price target raised by analysts at Stifel Nicolaus from $2.00 to $3.00. They now have a "hold" rating on the stock.
Low
Report
Neumora Therapeutics (NASDAQ:NMRA) had its price target raised by analysts at Stifel Nicolaus from $2.00 to $3.00. They now have a "hold" rating on the stock.
11/6
08:04 am
nmra
Neumora Therapeutics GAAP EPS of -$0.35 misses by $0.02 [Seeking Alpha]
Medium
Report
Neumora Therapeutics GAAP EPS of -$0.35 misses by $0.02 [Seeking Alpha]
11/6
07:00 am
nmra
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Low
Report
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
11/3
07:00 am
nmra
Neumora Therapeutics to Participate in Upcoming Conferences in November
Low
Report
Neumora Therapeutics to Participate in Upcoming Conferences in November
10/28
08:09 am
nmra
Neumora Therapeutics (NASDAQ:NMRA) had its price target raised by analysts at Needham & Company LLC from $6.00 to $8.00. They now have a "buy" rating on the stock.
Low
Report
Neumora Therapeutics (NASDAQ:NMRA) had its price target raised by analysts at Needham & Company LLC from $6.00 to $8.00. They now have a "buy" rating on the stock.
10/27
08:34 am
nmra
Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $14.00 price target on the stock.
Medium
Report
Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $14.00 price target on the stock.
10/27
07:00 am
nmra
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
Medium
Report
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
10/27
06:30 am
nmra
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
Medium
Report
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
10/8
12:30 pm
nmra
Neumora Therapeutics (NASDAQ:NMRA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Neumora Therapeutics (NASDAQ:NMRA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/1
07:38 am
nmra
Neumora Therapeutics to Host Virtual R&D Day on October 27 [Yahoo! Finance]
Medium
Report
Neumora Therapeutics to Host Virtual R&D Day on October 27 [Yahoo! Finance]
10/1
07:00 am
nmra
Neumora Therapeutics to Host Virtual R&D Day on October 27
Low
Report
Neumora Therapeutics to Host Virtual R&D Day on October 27
9/16
08:07 am
nmra
Neumora Therapeutics (NASDAQ:NMRA) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.
Neutral
Report
Neumora Therapeutics (NASDAQ:NMRA) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.